NASDAQ:GLYC GlycoMimetics - GLYC Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding GlycoMimetics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $3.09 +0.06 (+1.98%) (As of 02/3/2023 12:00 AM ET) Add Compare Share Share Today's Range$2.97▼$3.1250-Day Range$2.04▼$3.3952-Week Range$0.51▼$3.60Volume380,625 shsAverage Volume986,260 shsMarket Capitalization$161.99 millionP/E RatioN/ADividend YieldN/APrice TargetN/A ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability GlycoMimetics MarketRank™ ForecastAnalyst RatingN/AUpside/DownsideN/AShort InterestHealthy1.56% of Float Sold ShortDividend StrengthN/ASustainability-0.55Upright™ Environmental ScoreNews SentimentN/AInsider TradingSelling Shares$2.85 M Sold Last QuarterProj. Earnings GrowthGrowingFrom ($0.91) to ($0.65) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.95 out of 5 starsMedical Sector608th out of 1,028 stocksPharmaceutical Preparations Industry294th out of 501 stocks N/A Analyst's Opinion Consensus RatingThere is not enough analysis data for GlycoMimetics. Previous Next 3.0 Short Interest Percentage of Shares Shorted1.56% of the float of GlycoMimetics has been sold short.Short Interest Ratio / Days to CoverGlycoMimetics has a short interest ratio ("days to cover") of 1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in GlycoMimetics has recently increased by 7.78%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldGlycoMimetics does not currently pay a dividend.Dividend GrowthGlycoMimetics does not have a long track record of dividend growth. Previous Next 4.6 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreGlycoMimetics has received a 73.56% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is false driven by its "Preclinical research services for physical health", "Clinical research services for physical health", and "Basic medical research services" products. See details.Environmental SustainabilityThe Environmental Impact score for GlycoMimetics is -0.55. Previous Next 2.2 News and Social Media Coverage News SentimentGlycoMimetics has a news sentiment score of -0.01. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.46 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for GlycoMimetics this week, compared to 1 article on an average week.Search Interest15 people have searched for GLYC on MarketBeat in the last 30 days. This is an increase of 15% compared to the previous 30 days.MarketBeat Follows10 people have added GlycoMimetics to their MarketBeat watchlist in the last 30 days. This is an increase of 67% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, GlycoMimetics insiders have sold 628.61% more of their company's stock than they have bought. Specifically, they have bought $390,500.00 in company stock and sold $2,845,225.00 in company stock.Percentage Held by InsidersOnly 8.00% of the stock of GlycoMimetics is held by insiders.Percentage Held by Institutions49.50% of the stock of GlycoMimetics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for GlycoMimetics are expected to grow in the coming year, from ($0.91) to ($0.65) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of GlycoMimetics is -3.03, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of GlycoMimetics is -3.03, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioGlycoMimetics has a P/B Ratio of 1.96. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About GlycoMimetics (NASDAQ:GLYC) StockGlycoMimetics, Inc. engages in the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in which carbohydrate biology plays a key role. It develops proprietary glycomimetics that inhibit disease related functions of carbohydrates. The company was founded by Rachel K. King and John L. Magnani on April 4, 2003 and is headquartered in Rockville, MD.Read More Receive GLYC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for GlycoMimetics and its competitors with MarketBeat's FREE daily newsletter. Email Address GLYC Stock News HeadlinesJanuary 30, 2023 | americanbankingnews.comInsider Selling: GlycoMimetics, Inc. (NASDAQ:GLYC) Major Shareholder Sells $2,125,572.16 in StockJanuary 22, 2023 | finance.yahoo.comGlycoMimetics, Inc.'s (NASDAQ:GLYC) Shift From Loss To ProfitFebruary 5, 2023 | Tradewins (Ad)Know Your Profit Potential BEFORE You Trade!I’m Chuck Hughes, ten-time trading champion and author of the coveted e-book, “Options Trading Made Easy”, the strategy guide that will teach you to calculate your trade’s profit potential before you risk any capital. Click here for a free copy now! January 22, 2023 | finance.yahoo.comThis Small Pharma Company Could Develop Into a Nice TradeDecember 26, 2022 | finance.yahoo.comIs GlycoMimetics (NASDAQ:GLYC) In A Good Position To Invest In Growth?December 12, 2022 | finance.yahoo.comGlycoMimetics Announces New Uproleselan Clinical Data in Both Frontline Unfit and Treated Secondary Acute Myeloid Leukemia presented at ASH Annual MeetingDecember 3, 2022 | americanbankingnews.comGlycoMimetics (NASDAQ:GLYC) Coverage Initiated by Analysts at StockNews.comDecember 2, 2022 | finance.yahoo.comIs GlycoMimetics (GLYC) Outperforming Other Medical Stocks This Year?February 5, 2023 | Investor Place Media (Ad)Cash Holders STILL Aren't Taking Steps to PrepareStocks are crashing... inflation is through the roof... multiple industries are getting hit hard... Americans are fearful of what might happen to their stock portfolios right now -- and who's to blame them? But former Wall Street money manager Louis Navellier says all it takes is being on the right side of this force driving the massive divide. Take action today and watch his exclusive presentation -- absolutely free of charge -- to see how you should be prepping for this phenomenon.December 2, 2022 | finance.yahoo.comIndividual investors account for 44% of GlycoMimetics, Inc.'s (NASDAQ:GLYC) ownership, while hedge funds account for 18%November 23, 2022 | finance.yahoo.comAfter Golden Cross, GlycoMimetics (GLYC)'s Technical Outlook is BrightNovember 12, 2022 | finance.yahoo.comGlycoMimetics Third Quarter 2022 Earnings: US$0.16 loss per share (vs US$0.34 loss in 3Q 2021)November 10, 2022 | finance.yahoo.comInsiders at GlycoMimetics, Inc. (NASDAQ:GLYC) recouped some losses this week after buying this year, still down US$49kNovember 9, 2022 | finance.yahoo.comGlycoMimetics Reports Highlights and Financial Results for Third Quarter 2022November 8, 2022 | finance.yahoo.comGlycoMimetics to Participate in Two Upcoming Investor ConferencesNovember 3, 2022 | finance.yahoo.comGlycoMimetics Announces New Uproleselan Clinical Data in Both Frontline Unfit and Treated Secondary Acute Myeloid Leukemia Will Be Presented at ASH Annual MeetingNovember 2, 2022 | finance.yahoo.comGlycoMimetics to Report Third Quarter Financial Results on November 9, 2022October 19, 2022 | globenewswire.comAcute Myeloid Leukemia Market Size to Surpass US$ 4.31 Billion by 2030 - Growth Plus Reports - GlobeNewswireOctober 19, 2022 | benzinga.comVenous Thromboembolism Pipeline Assessment – Clinical Trials, FDA, EMA, and PMDA Approvals, Emerging Drug - BenzingaOctober 13, 2022 | businesswire.comVaso-occlusive Crisis-associated with Sickle Cell Disease Drug Pipeline Report 2022 - ResearchAndMarkets.com - Business WireOctober 11, 2022 | businesswire.comBIO Announces Appointment of Interim CEO - Business WireOctober 4, 2022 | finance.yahoo.comGlycoMimetics (GLYC) Upgraded to Buy: Here's WhySeptember 21, 2022 | benzinga.com12 Health Care Stocks Moving In Tuesday's Intraday Session - bluebird bio (NASDAQ:BLUE), Apexigen (NASDAQ - BenzingaSeptember 16, 2022 | benzinga.comSickle Cell Disease Treatment Global Market to Reach $4 Billion by 2027 - BenzingaSeptember 14, 2022 | streetinsider.comForm 425 Maxpro Capital Acquisiti Filed by: Apollomics Inc. - StreetInsider.comSeptember 9, 2022 | benzinga.comSickle Cell Disease Treatment Global Market Report 2022: Increase in the Number of Individuals Suffering - BenzingaSeptember 8, 2022 | nasdaq.comGlycoMimetics Says Edwin Rock Joins As Chief Medical Officer - NasdaqSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive GLYC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for GlycoMimetics and its competitors with MarketBeat's FREE daily newsletter. Email Address GLYC Company Calendar Last Earnings11/09/2022Today2/04/2023Next Earnings (Estimated)3/02/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:GLYC CUSIPN/A CIK1253689 Webwww.glycomimetics.com Phone(240) 243-1201Fax301-738-2137Employees52Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($1.02) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-63,430,000.00 Net MarginsN/A Pretax Margin-57,921.50% Return on Equity-85.00% Return on Assets-72.59% Debt Debt-to-Equity RatioN/A Current Ratio6.95 Quick Ratio6.95 Sales & Book Value Annual Sales$92,625.00 Price / Sales1,748.88 Cash FlowN/A Price / Cash FlowN/A Book Value$1.58 per share Price / Book1.96Miscellaneous Outstanding Shares52,424,000Free Float48,230,000Market Cap$161.99 million OptionableOptionable Beta2.08 Key ExecutivesHarout SemerjianPresident, Chief Executive Officer & DirectorBrian M. HahnChief Financial Officer & Senior VP-FinanceJohn L. MagnaniChief Scientific Officer & Senior VP-ResearchDeepak TiwariVice President-Technical OperationsEdwin P. RockChief Medical Officer & Senior Vice PresidentKey CompetitorsChimerixNASDAQ:CMRXBioVieNASDAQ:BIVISpectrum PharmaceuticalsNASDAQ:SPPILiminal BioSciencesNASDAQ:LMNLInterCureNASDAQ:INCRView All CompetitorsInsiders & InstitutionsIntellectus Partners LLCSold 38,770 shares on 2/2/2023Ownership: 0.156%Simplex Trading LLCBought 1,000 shares on 2/2/2023Ownership: 0.000%AE Wealth Management LLCBought 26,898 shares on 1/31/2023Ownership: 0.051%Scott D SandellSold 652,016 sharesTotal: $2.13 M ($3.26/share)Scott D SandellSold 71,362 sharesTotal: $196,959.12 ($2.76/share)View All Insider TransactionsView All Institutional Transactions GLYC Stock - Frequently Asked Questions Should I buy or sell GlycoMimetics stock right now? 1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for GlycoMimetics in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" GLYC shares. View GLYC analyst ratings or view top-rated stocks. How have GLYC shares performed in 2023? GlycoMimetics' stock was trading at $3.03 at the beginning of 2023. Since then, GLYC stock has increased by 2.0% and is now trading at $3.09. View the best growth stocks for 2023 here. When is GlycoMimetics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, March 2nd 2023. View our GLYC earnings forecast. How were GlycoMimetics' earnings last quarter? GlycoMimetics, Inc. (NASDAQ:GLYC) announced its quarterly earnings results on Wednesday, November, 9th. The biotechnology company reported ($0.16) EPS for the quarter, beating the consensus estimate of ($0.26) by $0.10. What other stocks do shareholders of GlycoMimetics own? Based on aggregate information from My MarketBeat watchlists, some companies that other GlycoMimetics investors own include Exelixis (EXEL), TG Therapeutics (TGTX), Viking Therapeutics (VKTX), Cidara Therapeutics (cdtx), Celldex Therapeutics (CLDX), Dynavax Technologies (DVAX), Spectrum Pharmaceuticals (SPPI), Coherus BioSciences (CHRS), Verastem (VSTM) and Aldeyra Therapeutics (ALDX). What is GlycoMimetics' stock symbol? GlycoMimetics trades on the NASDAQ under the ticker symbol "GLYC." Who are GlycoMimetics' major shareholders? GlycoMimetics' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Intellectus Partners LLC (0.16%), AE Wealth Management LLC (0.05%), Simplex Trading LLC (0.00%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Brian M Hahn, Bvf Partners L P/Il, Daniel M Junius, Edwin Rock, John L Magnani, Patricia S Andrews and Scott D Sandell. View institutional ownership trends. How do I buy shares of GlycoMimetics? Shares of GLYC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is GlycoMimetics' stock price today? One share of GLYC stock can currently be purchased for approximately $3.09. How much money does GlycoMimetics make? GlycoMimetics (NASDAQ:GLYC) has a market capitalization of $161.99 million and generates $92,625.00 in revenue each year. The biotechnology company earns $-63,430,000.00 in net income (profit) each year or ($1.02) on an earnings per share basis. How can I contact GlycoMimetics? GlycoMimetics' mailing address is 9708 MEDICAL CENTER DRIVE, ROCKVILLE MD, 20850. The official website for the company is www.glycomimetics.com. The biotechnology company can be reached via phone at (240) 243-1201, via email at sannes@annesassociates.com, or via fax at 301-738-2137. This page (NASDAQ:GLYC) was last updated on 2/5/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.